Cases & Deals

  • Home
  • Practices
  • Puma Biotechnology asserts patent infringement claims against AstraZeneca's Tagrisso® (osimertinib) products for treatment of gefitinib and/or erlotinib-resistant non-small cell lung cancer

Share

Puma Biotechnology asserts patent infringement claims against AstraZeneca's Tagrisso® (osimertinib) products for treatment of gefitinib and/or erlotinib-resistant non-small cell lung cancer

September 2021

Client(s) Puma Biotechnology, Inc.

Jones Day is representing Puma Biotechnology, Inc. in a patent infringement action against defendants for infringement of United States Patent Nos. 10,603,314 and 10,596,162. The complaint alleges that defendants' commercial manufacture, use, offer for sale, sale, distribution, and/or importation of Tagrisso® (osimertinib) products for the treatment of gefitinib and/or erlotinib-resistant non-small cell lung cancer infringes the asserted patents.

Puma Biotechnology, Inc., et al. v. AstraZeneca Pharmaceuticals LP, et al., No. 1-21-cv-01338 (D. Del.)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.